Amari Trade Alliance LLP Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Amari Trade Alliance LLP Pharmaceutical Export Portfolio Dataset — 2 Products, $15.5K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Amari Trade Alliance LLP — Pharmaceutical Exporter Profile (2026) | 2 Products, $15.5K Trade | TransData Nexus

Amari Trade Alliance LLP

Indian Pharmaceutical Exporter · Antiviral & HIV Medications Specialist · $15.5K Total Trade · DGFT Verified

Amari Trade Alliance LLP is an Indian pharmaceutical exporter with a total trade value of $15.5K across 2 products in 2 therapeutic categories. Based on 12 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ledipasvir ($12.1K), Streptomycin ($3.3K), .

Amari Trade Alliance LLP — Export Portfolio & Destination Treemap

Amari Trade Alliance LLP pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Amari Trade Alliance LLP? — Company Overview & Market Position

Amari Trade Alliance LLP, established on February 21, 2020, is a pharmaceutical wholesaler and exporter headquartered in Mumbai, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) AAS-0125 and is registered with the Registrar of Companies (RoC) Mumbai. Its registered office is located at 206, Floor-2, Parvati Industrial Estate, Sitaram Jadhav Marg, Sun Mill Compound Lower Parel, Delisle Road, Mumbai, Maharashtra, 400013.

Amari Trade Alliance specializes in sourcing and supplying high-quality finished pharmaceutical formulations from renowned multinational companies (MNCs) and Indian multinationals. The company's product portfolio spans diverse therapeutic segments, including Oncology, Nephrology, Neurology, Cardiology, Urology, Orthopaedics, Ophthalmics, Virology, Antifungal, Critical Care, Contrast Media, Lifestyle Diseases, Hormonal, Antibiotics, and Food Supplements.

As of the latest available data, the company has a total obligation of contribution of ₹0.10 million. The most recent financial statements were filed on March 31, 2025. The leadership comprises two designated partners: Afzal Hasam Chawda and Jasmina Afzal Chawda. Afzal Hasam Chawda has been associated with the company since its inception, while Jasmina Afzal Chawda joined on October 5, 2022.

What Does Amari Trade Alliance LLP Export? — Product Portfolio Analysis

Product Portfolio — Top 2 by Export Value

Amari Trade Alliance LLP exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ledipasvir	Antiviral & HIV Medications	$12.1K	4	1.1%	8
2	Streptomycin	Antibiotics	$3.3K	8	0.6%	7

Amari Trade Alliance LLP exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $15.5K. The top category is Antiviral & HIV Medications (78.5% of portfolio), followed by Antibiotics (21.5%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Amari Trade Alliance LLP — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Amari Trade Alliance operates a state-of-the-art warehouse and distribution center in Mumbai, strategically located to serve clients globally. The facility is equipped with modern infrastructure, including a 16,000-liter cold storage unit, ensuring the efficacy of cold chain shipments. The company boasts a production capacity of up to 10 million tablets per day, enabling it to handle both small and large batch sizes efficiently.

3Key Leadership

The leadership team of Amari Trade Alliance LLP comprises two designated partners:

Afzal Hasam Chawda: Serving as a designated partner since the company's inception on February 21, 2020, Afzal has been instrumental in steering the company's strategic direction and operations.

Jasmina Afzal Chawda: Appointed as a designated partner on October 5, 2022, Jasmina brings valuable expertise and has contributed to the company's growth and expansion.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Amari Trade Alliance LLP Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Amari Trade Alliance LLP's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's total export value stands at $15,000 USD, with 12 shipments across two therapeutic categories: Antiviral & HIV Medications (78.5%) and Antibiotics (21.5%). The top five products exported are Ledipasvir ($12,000 USD, Rank #8, 1.1% market share) and Streptomycin ($3,000 USD, Rank #7, 0.6% market share).

2Emerging Markets

Amari Trade Alliance has made significant inroads into emerging markets, particularly in Africa and the Middle East. The company's strategic focus on providing life-saving medicines for rare diseases has facilitated its penetration into these regions. By offering a comprehensive range of pharmaceutical dosage forms, including tablets, capsules, syrups, and injections, Amari caters to diverse therapeutic needs, enhancing its presence in these markets.

3Geographic Strategy

Amari Trade Alliance's export portfolio is highly concentrated, with the top five products accounting for 100% of its exports. This concentration indicates a focused approach in its product offerings. The company's strategic direction appears to be centered on consolidating its position in specific therapeutic categories, particularly Antiviral & HIV Medications and Antibiotics, to leverage market opportunities effectively.

Amari Trade Alliance LLP — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, Amari Trade Alliance LLP has not publicly disclosed any FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. This lack of publicly available information suggests that the company may not currently have FDA approvals for its products or manufacturing facilities.

2WHO & EU GMP

Amari Trade Alliance has not publicly disclosed any WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status. The absence of such certifications indicates that the company may not have obtained these international quality accreditations for its products or manufacturing processes.

3CDSCO & Indian Regulatory

Amari Trade Alliance LLP has not publicly disclosed specific details regarding its manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, or export No Objection Certificates (NOCs). The lack of publicly available information suggests that the company may not have obtained these regulatory approvals or certifications.

Amari Trade Alliance LLP — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Amari Trade Alliance operates in a competitive pharmaceutical export market, with several established players offering similar product portfolios. While specific market share data is not publicly available, the company's focus on high-quality finished formulations and its strategic emphasis on life-saving medicines for rare diseases position it as a competitive entity in the market. However, the lack of publicly disclosed regulatory approvals may impact its competitiveness in certain markets.

2Key Differentiators

Amari Trade Alliance's commitment to providing life-saving medicines for rare diseases distinguishes it from competitors. The company's extensive product portfolio across various therapeutic segments, coupled with its capacity to handle both small and large batch sizes, enhances its appeal to a diverse clientele. Additionally, the state-of-the-art warehouse and cold storage facilities underscore its dedication to maintaining product quality and efficacy.

3Strategic Position

Amari Trade Alliance's current strategic direction appears to be focused on consolidating its position in specific therapeutic categories, particularly Antiviral & HIV Medications and Antibiotics. The company's emphasis on providing life-saving medicines for rare diseases and its capacity to handle large-scale production suggest a potential for future expansion into new markets and therapeutic areas. However, obtaining international regulatory approvals, such as FDA, WHO-GMP, and EU GMP certifications, may be crucial for the company's growth and acceptance in global markets.

Buyer Due Diligence Brief — Evaluating Amari Trade Alliance LLP as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Amari Trade Alliance has demonstrated a consistent track record in exporting pharmaceutical products, with a total export value of $15,000 USD across 12 shipments. The company's focus on high-quality finished formulations and its capacity to handle large-scale production indicate reliability in meeting client demands. However, the lack of publicly disclosed regulatory approvals may raise concerns regarding product quality and compliance with international standards.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the company's products are approved by the U.S. Food and Drug Administration (FDA). Verification can be done through the FDA's official website or by contacting the company directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with the World Health Organization's Good Manufacturing Practice standards. This can be verified by checking the WHO's official list of prequalified manufacturers.

Frequently Asked Questions — Amari Trade Alliance LLP

How many pharmaceutical products does Amari Trade Alliance LLP export from India?

Amari Trade Alliance LLP exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Ledipasvir ($12.1K), Streptomycin ($3.3K). Total export value is $15.5K.

What is Amari Trade Alliance LLP's total pharmaceutical export value?

Amari Trade Alliance LLP's total pharmaceutical export value is $15.5K, based on 12 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Amari Trade Alliance LLP cover?

Amari Trade Alliance LLP exports across 2 therapeutic categories. The largest are Antiviral & HIV Medications (78.5%, 1 products), Antibiotics (21.5%, 1 products).

Get Full Amari Trade Alliance LLP Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.